NasdaqGS:QDELMedical Equipment
FDA Clearance and Cardiac Diagnostic Expansion Could Be a Game Changer for QuidelOrtho (QDEL)
Earlier this month, QuidelOrtho Corporation announced FDA clearance for its VITROS High Sensitivity Troponin assay, reported a quarterly net loss of US$733 million on sales of US$699.9 million, and issued 2025 guidance projecting total revenues between US$2.68 billion and US$2.74 billion.
Alongside these financial disclosures, the company highlighted over US$140 million in recent cost savings and a product pipeline expansion into cardiac diagnostics, signaling ongoing efforts to improve...